Back

Stroke induces early recurrent vascular events by inflammasome-dependent atherosclerotic plaque rupture

Cao, J.; Roth, S.; Zhang, S.; Kopczak, A.; Georgakis, M. K.; Li, X.; Dutsch, A.; Liman, T. G.; Endres, M.; Brough, D.; Green, J. P.; Wernsdorf, S. R.; Fürle, C.; Carofiglio, O.; Zhu, J.; Asare, Y.; DEMDAS Study Group, ; Dichgans, M. K.; Sager, H. B.; Grosse, G. M.; Liesz, A.

2023-02-03 immunology
10.1101/2023.02.01.526550 bioRxiv
Show abstract

The risk of early recurrent events after stroke remains high despite currently established secondary prevention strategies. Risk is particularly high in patients with atherosclerosis, with more than 10% of patients experiencing early recurrent events. However, despite the enormous medical burden of this clinical phenomenon, the underlying mechanisms leading to increased vascular risk and recurrent stroke are largely unknown. Here, using a novel mouse model of stroke-induced recurrent ischemia, we show that stroke leads to activation of the AIM2 inflammasome in vulnerable atherosclerotic plaques via an increase of circulating cell-free DNA from the ischemic tissue. Enhanced plaque inflammation post-stroke results in plaque destabilization and atherothrombosis, finally leading to arterio-arterial embolism and recurrent stroke within days after the index stroke. We confirm key steps of plaque destabilization also after experimental myocardial infarction and in carotid artery plaque samples from patients with acute stroke. Neutralization of cell-free DNA by DNase treatment or inhibition of inflammasome activation reduced the rate of stroke recurrence after experimental stroke. Our findings present an explanation for the high recurrence rate after incident ischemic events in atherosclerotic patients. The detailed mechanisms uncovered here provide so far clinically uncharted therapeutic targets for which we show high efficacy to prevent recurrent events. Targeting DNA-mediated inflammasome activation after remote tissue injury represents a promising avenue for further clinical development in the prevention of early recurrent events.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Cardiovascular Research
33 papers in training set
Top 0.1%
22.1%
2
Nature Communications
5641 papers in training set
Top 13%
13.2%
3
eLife
5828 papers in training set
Top 16%
6.8%
4
Cell Reports
1498 papers in training set
Top 6%
5.5%
5
Stroke
40 papers in training set
Top 0.3%
4.9%
50% of probability mass above
6
Atherosclerosis
30 papers in training set
Top 0.2%
4.1%
7
Nature
645 papers in training set
Top 5%
2.7%
8
Science Translational Medicine
127 papers in training set
Top 0.9%
2.7%
9
Science Advances
1243 papers in training set
Top 13%
2.7%
10
Science
477 papers in training set
Top 3%
2.5%
11
Journal of Clinical Investigation
179 papers in training set
Top 2%
2.5%
12
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 22%
2.4%
13
Circulation Research
47 papers in training set
Top 0.7%
2.1%
14
Nature Immunology
79 papers in training set
Top 1%
2.1%
15
EMBO Molecular Medicine
95 papers in training set
Top 0.8%
1.7%
16
Cardiovascular Research
37 papers in training set
Top 0.7%
1.5%
17
Immunity
67 papers in training set
Top 1%
1.3%
18
Journal of Experimental Medicine
119 papers in training set
Top 2%
1.3%
19
Circulation
74 papers in training set
Top 2%
1.3%
20
Med
39 papers in training set
Top 0.4%
1.1%
21
Cell
431 papers in training set
Top 8%
1.1%
22
Journal of Cerebral Blood Flow & Metabolism
42 papers in training set
Top 0.7%
0.8%
23
iScience
1154 papers in training set
Top 34%
0.8%
24
Autophagy
39 papers in training set
Top 0.7%
0.6%
25
Nature Aging
60 papers in training set
Top 2%
0.6%